Revise laws related to experimental treatments

2025 Regular Session Introduced by Ken Bogner

SB 535 enhances access to experimental treatments for patients with serious conditions, streamlining processes for providers and encouraging insurance coverage.

Chapter Number Assigned

#health(seealso:healthcareservices;safety) #healthcareservices(seealso:health) #revenue #state #rulemaking #safety(seealso:health)

Bill Overview

Bill Number: SB 535
Title: Revise laws related to experimental treatments
Status: Chapter Number Assigned
Introduced: November 04, 2024
Primary Sponsor: Kenneth Bogner
Related Bills: LC 780 (replaces)

SB 535 aims to update and revise existing laws concerning the use of experimental treatments within the healthcare system. The bill is designed to enhance patient access to innovative therapies while ensuring safety and regulatory compliance.

Purpose and Intent

The primary intent of SB 535 is to facilitate the availability of experimental treatments for patients with serious or life-threatening conditions. The bill seeks to streamline the process for healthcare providers and patients to access these treatments, which may not yet be fully approved by regulatory bodies.

Key Provisions

Access to Experimental Treatments: The bill allows healthcare providers to offer experimental treatments to patients who have exhausted all other conventional treatment options.

Informed Consent Requirements: Providers must ensure that patients are fully informed about the potential risks and benefits of the experimental treatments.

Regulatory Framework: Establishes a clear regulatory framework for the oversight of experimental treatments, including guidelines for clinical trials and patient eligibility.

Insurance Coverage Considerations: The bill encourages insurance providers to cover certain experimental treatments under specific circumstances, promoting broader access for patients.

Impact

Patients: Individuals suffering from serious health conditions will benefit from increased access to potentially life-saving experimental treatments.

Healthcare Providers: The bill provides a clearer pathway for providers to administer experimental therapies, reducing bureaucratic hurdles.

Insurance Companies: Insurers may need to adapt their policies to accommodate coverage for experimental treatments, which could lead to changes in premium structures.

Legislative Timeline

November 04, 2024: Bill introduced and referred to the Senate Committee on Public Health, Welfare and Safety.

April 2025: The bill underwent multiple readings and amendments in both the Senate and House, with significant discussions in the Human Services Committee.

May 2025: The bill was signed by the Governor and assigned a chapter number, marking its passage into law.

Conclusion

SB 535 represents a significant step towards improving access to experimental treatments for patients facing critical health challenges. By revising existing laws and establishing a supportive regulatory framework, the bill aims to foster innovation in healthcare while prioritizing patient safety and informed consent.

Bill